<DOC>
	<DOCNO>NCT02621359</DOCNO>
	<brief_summary>Helicobacter pylorus ( H. pylorus ) infection global health problem associate peptic ulcer , chronic gastritis , duodenitis , stomach cancer . Therefore , eradication pathogen critical importance reduce H. pylori-related complication . However , due increase antibiotic resistance , eradication Helicobacter pylori become challenge . With great decline eradication rate standard triple therapy Helicobacter pylori 70 % many country . Treatment triple therapy , frequently recommend , fails eradicate H. pylori approximately 20 % case .</brief_summary>
	<brief_title>A Two Week Nitazoxanidebased Quadruple Regimen</brief_title>
	<detailed_description>Designing new rescue regimen achieve great 85 % eradication rate important target current research . Unfortunately , frequently use `` rescue '' `` salvage '' therapy bismuth quadruple therapy consist proton pump inhibitor ( PPI ) , tetracycline , metronidazole , bismuth [ 11 ] . This rescue therapy inexpensive , relatively effective average eradication rate 70 % use second-line therapy . However , disadvantage bismuth base quadruple therapy include large daily number pill ( sometimes exceed 18 pill ) , increase dosing frequency ( four time daily ) , frequent side effect .</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Patients helicobacter infection . standard triple therapy ( clarithromycinbased triple therapy ) fail Patients 18 65 year age . Those coexist serious illness liver cirrhosis , uremia gastrointestinal malignancy pregnancy/lactation contraindication allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>